ScreenerHero

IMMU Mendus AB (publ)

STO · SE · Healthcare · Biotechnology · mendus.com
6.150SEK-0.81%Mkt Cap: 37.34M $P/E: —

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap37.34M USD
Enterprise Value34.01M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-10.83M USD
Revenue/Share—
Last Price6.150 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-12.65
PEG—
EV/EBITDA-3.84
EV/Revenue—
P/S—
P/B0.73
EPS (TTM)-1.79
EPS (Forward)-0.49
52W Range
3.86049% of range8.490
52W High8.490 SEK
52W Low3.860 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-19.36%
ROA-18.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.80M USD
CapEx (TTM)29.37K USD
FCF Margin—
FCF Yield-1.91%
Net Debt-4.01M USD
Net Debt/EBITDA0.45
Balance Sheet
Debt/Equity0.03
Current Ratio1.14
Quick Ratio1.06
Book Value/Sh8.51 SEK
Cash/Share0.93 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 3, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.95 SEK
Upside (mean)+452.0%
Target Range17.90 SEK – 50.00 SEK
17.90+452.0% to mean50.00
# Analysts2
Ownership
Shares Out.63.48M
Float23.04M
Insiders62.84%
Institutions16.06%
Technical
SMA 506.819 (-9.8%)
SMA 2005.688 (+8.1%)
Beta0.76
S&P 52W Chg14.58%
Avg Vol (30d)21.35K
Avg Vol (10d)12.46K
Technical Indicators
RSI (14)35.4
MACD-0.1679
MACD Signal-0.1084
MACD Hist.-0.0595
BB Upper7.324 SEK
BB Middle6.634 SEK
BB Lower5.944 SEK
BB Width20.81%
ATR (14)0.3373 SEK
Vol Ratio (20d)0.55x